LCTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
LCTX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive momentum and strong bullish options sentiment, but the technical setup is still mixed and there is no fresh news or financial evidence to support a confident long-term purchase at this moment. Since the investor is impatient and wants a direct answer, the best call is to hold off rather than buy today.
Current pre-market price is 1.33, sitting just below resistance at 1.346 and above pivot support at 1.283. MACD is positive and expanding, which supports short-term upward momentum. RSI_6 at 56.49 is neutral, so the stock is not overbought. However, the moving averages are still bearish with SMA_200 > SMA_20 > SMA_5, which means the broader trend remains weak despite the recent bounce. Overall, the short-term trend is improving, but the long-term trend is still not strong enough for a beginner-friendly long-term entry.
["Canaccord initiated coverage with a Buy rating and $9 price target.", "B. Riley raised its price target to $4 from $3 and kept a Buy rating.", "Analysts highlighted potential upside from Roche proceeding with clinical studies for OpRegen.", "Additional optimism around OPC1 and COR1 supports the pipeline narrative.", "Options positioning is strongly bullish with very low put-call ratios.", "Technical momentum is improving, with MACD turning positive and expanding."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "The broader trend is still bearish because SMA_200 is above shorter moving averages.", "Hedge funds are neutral and insiders are neutral, so there is no strong conviction buying signal.", "No recent congress trading data is available.", "Financial snapshot is unavailable, limiting confidence in the latest quarter performance."]
Latest quarter financial data was not available due to a data error, so a quarter-by-quarter growth assessment cannot be confirmed. Because of that, there is no visible evidence here of revenue acceleration, profitability improvement, or a clear fundamental inflection that would justify an immediate long-term buy.
Analyst sentiment has improved. On 2026-04-28, Canaccord initiated Buy coverage with a $9 target, and on 2026-03-25, B. Riley increased its target to $4 from $3 while maintaining Buy. This is a positive trend in price targets and coverage outlook. The Wall Street pros view is constructive on the pipeline and partnership potential, but the lack of supporting financial data and the still-bearish long-term chart make the case incomplete for a beginner long-term buyer.
